|Day's Range||173.55 - 177.92|
|52 Week Range||168.58 - 262.71|
|PE Ratio (TTM)||17.87|
|Dividend & Yield||5.12 (2.90%)|
|1y Target Est||N/A|
U.S. lawmakers said on Monday they wanted another $18.5 billion added to President Donald Trump's proposed defense budget of $603 billion to hire more troops and buy more aircraft and ships in fiscal 2018. Republican House of Representatives Armed Services Committee Chairman Mac Thornberry released a proposed defense policy bill intended to address military readiness and the Department of Defense's unfunded requirements list, which is hovering at $33 billion, House staff told reporters on Monday. The $621.5 billion proposed base spending plan for the Pentagon and defense related expenses at the U.S. Department of Energy was more than 13 percent higher than the 2018 defense spending budget cap of $549 billion which would need to be raised by Congress for the legislation to be enacted.
Mylan N.V. is best known for producing EpiPen emergency allergy treatments and generic drugs. Since 2011, Mylan has bought 99 percent stakes in five companies across the U.S. that own plants which process coal to reduce smog-causing emissions. Mylan is one of only a few public companies, and the only publicly-traded pharmaceutical maker, that uses these tax credits, a Reuters review of a comprehensive database of filings with the U.S. Securities and Exchange Commission found.
Shares of Target Corporation, ExxonMobil, and W.W. Grainger are well off of their highs lately. Perhaps it's time to take a closer look.